Silverfin false false 31/12/2024 01/01/2024 31/12/2024 S Emmott 26/10/2020 25 February 2025 The principal activity of the Company during the year was that of fund management activities. 12974429 2024-12-31 12974429 bus:Director1 2024-12-31 12974429 2023-12-31 12974429 core:CurrentFinancialInstruments 2024-12-31 12974429 core:CurrentFinancialInstruments 2023-12-31 12974429 core:ShareCapital 2024-12-31 12974429 core:ShareCapital 2023-12-31 12974429 core:SharePremium 2024-12-31 12974429 core:SharePremium 2023-12-31 12974429 core:RetainedEarningsAccumulatedLosses 2024-12-31 12974429 core:RetainedEarningsAccumulatedLosses 2023-12-31 12974429 bus:OrdinaryShareClass1 2024-12-31 12974429 2024-01-01 2024-12-31 12974429 bus:FilletedAccounts 2024-01-01 2024-12-31 12974429 bus:SmallEntities 2024-01-01 2024-12-31 12974429 bus:AuditExemptWithAccountantsReport 2024-01-01 2024-12-31 12974429 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 12974429 bus:Director1 2024-01-01 2024-12-31 12974429 2023-01-01 2023-12-31 12974429 bus:OrdinaryShareClass1 2024-01-01 2024-12-31 12974429 bus:OrdinaryShareClass1 2023-01-01 2023-12-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: 12974429 (England and Wales)

SCIENTIFIC CAPITAL LIMITED

Unaudited Financial Statements
For the financial year ended 31 December 2024
Pages for filing with the registrar

SCIENTIFIC CAPITAL LIMITED

Unaudited Financial Statements

For the financial year ended 31 December 2024

Contents

SCIENTIFIC CAPITAL LIMITED

COMPANY INFORMATION

For the financial year ended 31 December 2024
SCIENTIFIC CAPITAL LIMITED

COMPANY INFORMATION (continued)

For the financial year ended 31 December 2024
DIRECTOR S Emmott
REGISTERED OFFICE 45 Gresham Street
London
EC2V 7BG
United Kingdom
COMPANY NUMBER 12974429 (England and Wales)
ACCOUNTANT Evelyn Partners LLP
Portwall Place
Portwall Lane
Bristol
BS1 6NA
SCIENTIFIC CAPITAL LIMITED

STATEMENT OF FINANCIAL POSITION

As at 31 December 2024
SCIENTIFIC CAPITAL LIMITED

STATEMENT OF FINANCIAL POSITION (continued)

As at 31 December 2024
Note 2024 2023
£ £
Current assets
Investments 5 20,886 24,674
Cash at bank and in hand 34,489 54,587
55,375 79,261
Creditors: amounts falling due within one year 3 ( 2,465) ( 7,468)
Net current assets 52,910 71,793
Total assets less current liabilities 52,910 71,793
Net assets 52,910 71,793
Capital and reserves
Called-up share capital 4 2 2
Share premium account 100,000 100,000
Profit and loss account ( 47,092 ) ( 28,209 )
Total shareholder's funds 52,910 71,793

For the financial year ending 31 December 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

These financial statements have been prepared in accordance with the provisions of FRS 102 Section 1A – small entities. The financial statements of Scientific Capital Limited (registered number: 12974429) were approved and authorised for issue by the Director on 25 February 2025. They were signed on its behalf by:

S Emmott
Director
SCIENTIFIC CAPITAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2024
SCIENTIFIC CAPITAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2024
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Scientific Capital Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is 45 Gresham Street, London, EC2V 7BG, United Kingdom.

The financial statements have been prepared in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

Going concern

The financial statements have been prepared on a going concern basis.

The director has made an assessment in preparing these financial statements as to whether the Company is a going concern and have concluded that there are no material uncertainties that may cast significant doubt on the Company's ability to continue as a going concern for a period of at least 12 months from the date of approval of these financial statements.

Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Statement of Financial Position date are reported at the rates of exchange prevailing at that date.

Exchange differences are recognised in the Statement of Comprehensive Income in the period in which they arise on monetary items.

Interest income

Interest income is recognised when it is probable that the economic benefits will flow to the Company and the amount of revenue can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

Finance costs

Finance costs are charged to the Statement of Comprehensive Income over the term of the debt using the effective interest method so the amount charged is at a constant rate on the carrying amount.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Statement of Financial Position date.

Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on enacted or substantively enacted tax rates and laws. Deferred tax assets and liabilities are not discounted.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit. Deferred tax assets are recognised only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilised.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts, except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

2. Employees

2024 2023
Number Number
Monthly average number of persons employed by the Company during the year, including the director 0 0

3. Creditors: amounts falling due within one year

2024 2023
£ £
Amounts owed to Group undertakings 2,426 7,428
Accruals 39 40
2,465 7,468

4. Called-up share capital

2024 2023
£ £
Allotted, called-up and fully-paid
95,485 Ordinary shares of £ 0.00002 each 2 2

On 3 August 2023, 8,475 Preferred shares were cancelled with a nominal value of £0.0002. The share premium account was reduced by £1,649,999.83.

On 23 August 2023, 4,515 Deferred shares with a nominal value £0.00002 were repurchased for cancellation. On the same date 4,515 Deferred shares were cancelled.

5. Current asset investments

2024 2023
£ £
Cash held for investments 20,886 24,674